Tag: Illumina/GRAIL
-
Draconian but unavoidable? Illumina’s quest for GRAIL ends in a record fine
Sprint races can be decided by hundredths of a second. But the sprinter who pushes off before the starting gun sounds “jumps the gun” and faces harsh punishment. In our never-ending attempts to make competition law sound cool, practitioners refer to the completion of a deal before mandatory clearance is obtained as “gun jumping”, even…
-
Illumina/Grail: An unholy war continues
The European Commission has blocked a merger that did not meet any European jurisdictional thresholds for the first time. In a case that has seen the Commission pushing at the boundaries of its remit, it has prohibited Illumina’s $8 billion acquisition of GRAIL. Article 22 EUMR The Illumina/GRAIL merger did not meet the thresholds under…
-
Legitimately expected: Commission may review Illumina/GRAIL deal
Today the General Court handed down its hotly anticipated judgment in the Illumina/GRAIL merger, deciding that the European Commission has jurisdiction to review the merger. This judgment is hugely consequential, as it confirms that EU Member States have the power to refer mergers to the Commission even when those mergers do not meet the national…
-
The Amici Curiosi – And other developments in Illumina/GRAIL
In this post, we share the latest developments in the Illumina/GRAIL merger. This case involves the now completed acquisition by Illumina of GRAIL, a company that has developed a test, which has shown the ability to detect multiple cancers from a single blood draw. GRAIL was founded by Illumina but spun off in 2016. Illumina…